Online inquiry

IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11295MR)

This product GTTS-WQ11295MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGAV&ITGB3 gene. The antibody can be applied in Sarcoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001144999.3; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685; 3690
UniProt ID P06756; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11295MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10892MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ12524MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ12485MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NN-8226
GTTS-WQ13325MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-06741086
GTTS-WQ10044MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ12688MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ8563MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ8409MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HS006
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW